《新股消息》依生生物製藥計劃年內來港上市 集資2億美元
路透旗下IFR報道,內地依生生物製藥計劃來港上市,集資約2億美元,目標今年內掛牌。
官網資料顯示,依生生物致力於開發抗腫瘤和抗病毒感染的創新生物治療藥物,旗下已經進入開發階段的產品包括用於治療晚期實體瘤的YS-ON-001、預防乙型肝炎感染的YS-HBV-001疫苗、治療乙型肝炎感染的生物大分子藥物YS-HBV-002,以及用於狂犬病毒暴露後快速保護的皮卡狂犬病疫苗等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.